Bio Green Med Solution, Inc. (BGMS) Key Metrics
BGMS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.0M
- Enterprise value
- $2.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.2
- Price / book
- 0.9
- EV / EBITDA
- 0.0
- Dividend yield
- —
- Beta
- −0.38
BGMS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBGMS returns How much profit the business earns on the capital it uses.
BGMS financial health Debt, liquidity and how easily interest is covered.
BGMS efficiency & capital use Working capital cycle and where the cash goes.
BGMS valuation history
BGMS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BGMS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BGMS cash returned to shareholders
BGMS price vs earnings per share
BGMS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $3.2M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$269,089 | — | — | — | — | — | — | — | — | — |
| Price / sales | 4.3 | — | — | — | — | — | — | — | — | — |
| Price / book | 0.5 | — | — | — | — | — | — | — | — | — |
| EV / sales | -0.4 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −92.7% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −147.5% | — | — | — | — | — | — | — | — | — |
| Dividend yield | 1.9% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 1.9% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.48 | $91.20 | $640.80 | $2,412.00 | $14,004.00 | $28,116.00 | $48,240.00 | $43,920.00 | $125,280.00 | $380,880.00 |
| Per share | ||||||||||
| Revenue per share | $0.34 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.37 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.18 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.18 | — | — | — | — | — | — | — | — | — |
| Cash per share | $1.60 | — | — | — | — | — | — | — | — | — |
| Book value per share | $3.13 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $2.41 | — | — | — | — | — | — | — | — | — |
| Dividends per share | $0.03 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 2.2M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −128.4% | — | −214.4% | −72.9% | −52.0% | −37.6% | −58.1% | −39.4% | −41.5% | −71.2% |
| Return on invested capital (ROIC) | — | — | — | — | — | −878.5% | — | — | — | — |
| Return on assets (ROA) | −48.8% | −173.8% | −122.4% | −59.6% | −46.2% | −32.4% | −44.6% | −31.8% | −32.7% | −53.1% |
| Return on tangible assets | −45.3% | −273.9% | −256.2% | −75.6% | −42.8% | −22.9% | −51.1% | −36.8% | −28.7% | −60.0% |
| Free cash flow margin | −638.6% | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2,000 | — | $37,000 | $106,000 | $30,000 | $1.1M | $1.2M | — | — | — |
| Cash & short-term investments | $3.5M | $3.1M | $3.4M | $18.3M | $36.6M | $33.4M | $11.9M | $17.5M | $24.0M | $16.7M |
| Net debt | −$3.5M | −$3.1M | −$3.3M | −$18.2M | −$36.5M | −$32.3M | −$10.7M | −$17.5M | −$24.0M | −$16.7M |
| Debt / equity | 0.00 | — | 0.06 | 0.01 | 0.00 | 0.03 | 0.10 | — | — | — |
| Debt / assets | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | — | — | — |
| Current ratio | 4.70 | 0.59 | 0.91 | 3.25 | 7.56 | 14.27 | 5.79 | 4.45 | 6.32 | 3.73 |
| Quick ratio | 3.66 | 0.59 | 0.91 | 3.25 | 7.56 | 14.27 | 5.79 | 4.45 | 6.32 | 3.73 |
| Working capital | $4.9M | −$2.6M | −$717,000 | $16.9M | $35.5M | $33.0M | $11.6M | $15.3M | $21.9M | $14.4M |
| Invested capital | $3.3M | −$5.3M | −$2.7M | $2.2M | $1.2M | $910,000 | $1.0M | −$2.2M | −$2.3M | −$2.4M |
| Tangible asset value | $5.3M | −$2.2M | $607,000 | $20.4M | $37.7M | $33.3M | $11.7M | $15.3M | $21.8M | $14.3M |
| Net current asset value | $4.9M | −$2.6M | −$754,000 | $16.8M | $35.5M | $31.9M | $10.4M | $15.2M | $21.7M | $14.2M |
| Graham net-net per share | $1.74 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $61,000 | $0 | $201,000 | $201,000 | $201,000 | $201,000 | $201,000 | $201,000 | $201,000 | $200,000 |
| Capex / revenue | 0.0% | 0.0% | 1.4% | — | — | — | — | 26.0% | — | 0.4% |
| Capex / depreciation | 0.00 | 0.00 | 0.19 | 0.22 | 0.63 | 4.80 | 0.50 | 1.34 | 0.41 | 0.02 |
| Stock-based compensation / revenue | 312.4% | 1,376.7% | 350.7% | — | — | — | — | 220.7% | — | 92.8% |
| R&D / revenue | 113.5% | 15,476.7% | 4,560.7% | — | — | — | — | 2,884.7% | — | 1,124.2% |
| SG&A / revenue | 1,033.1% | 12,539.5% | 1,599.5% | — | — | — | — | 3,580.7% | — | 654.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 365.0 | 13,454.1 | 3,301.1 | — | — | — | — | 3,640.3 | — | 515.9 |
| Days of inventory on hand | 414.7 | — | — | — | — | — | — | — | — | — |
| Days payables outstanding | 1,563.1 | 247,652.5 | 35,934.8 | 26,679.2 | 11,166.5 | 12,811.5 | 141.4 | 180.4 | 174.7 | 85.4 |
| Cash conversion cycle (days) | -783.3 | -234,198.4 | -32,633.8 | — | — | — | — | 3,459.9 | — | 430.4 |
| Receivables turnover | 1.00 | 0.03 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.71 |
| Payables turnover | 0.23 | 0.00 | 0.01 | 0.01 | 0.03 | 0.03 | 2.58 | 2.02 | 2.09 | 4.27 |
| Inventory turnover | 0.88 | — | — | — | — | — | — | — | — | — |
| Asset turnover | 0.12 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.04 |
| Average receivables | $747,000 | $1.6M | $3.8M | $4.5M | $2.8M | $1.3M | $1.4M | $1.5M | $1.8M | $1.2M |
| Average payables | $2.6M | $4.1M | $3.1M | $2.3M | $1.3M | $702,000 | $1.8M | $2.1M | $2.0M | $2.2M |
| Average inventory | $692,000 | $0 | — | — | — | — | — | — | — | — |
| Intangibles / total assets | 19.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BGMS's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BGMS valuation and financial ratios
Bio Green Med Solution earned a return on equity of −128.4% in fiscal 2025. It ended the year with $0.0 million of debt and $3.5 million in cash and short-term investments, a net cash position of $3.5 million. It returned $0.1 million to shareholders: $0.1 million in dividends and $0 in share buybacks.
See the BGMS income statement, the BGMS chart for price history, or the BGMS stock overview for the latest quote and news.
BGMS key metrics FAQ
What is Bio Green Med Solution's return on equity?
Bio Green Med Solution's return on equity (ROE) was −128.4% in fiscal 2025: net income of -$3.0 million on average shareholders' equity of $2.3 million.
How much debt does Bio Green Med Solution have?
Bio Green Med Solution had total debt of $0.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Bio Green Med Solution's dividend yield?
Bio Green Med Solution paid $0.1 million in dividends in fiscal 2025 ($0.03 per share), a payout ratio of —.
What is Bio Green Med Solution's free cash flow yield?
Bio Green Med Solution generated -$4.8 million of free cash flow in fiscal 2025, a free cash flow yield of −147.5% on its market value at year-end ($3.2 million).
What is Bio Green Med Solution's current ratio?
Bio Green Med Solution's current ratio was 4.70 at the end of fiscal 2025: current assets were 4.70 times current liabilities.